Hepatitis B vaccination and preemptive treatment of hepatitis B virus in liver transplantation

Current Opinion in Organ Transplantation

Volumn 11, Issue 6, 2006, Pages 594-598

  Hui, Chee Kin ^a   Cheung, Winnie W W ^a   Chan, See Ching ^a   Lo, Chung Mau ^a   Lau, George K K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

De novo hepatitis B virus infection; Prophylactic therapy; Transplantation

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS VACCINE; LAMIVUDINE;

CHEMOPROPHYLAXIS; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MONOTHERAPY; POSTOPERATIVE PERIOD; REVIEW; TREATMENT RESPONSE; VACCINATION;

EID: 33751240093     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32801040bf     Document Type: Review

References (47)

1. Brechot C, Degos F, Lugassy C, et al. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985; 312:270-276.
2. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131:59-68.
3. Fabia R, Levy M, Crippin J, et al. De novo hepatitis B infection after liver transplantation: sources of disease, incidence and impact. Liver Transplant Surg 1998; 4:119-127.
4. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113:1668-1674.
5. Hui CK, Lau E, Monto A, et al. Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantation. Am J Transplant 2006; 6:1600-1608.
6. Dodson SF, Issa S, Araya V, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64:1582-1584.
7. Hui CK, Sun J, Au WY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42:813-819.
8. Manzarbeitia C, Reich D, Ortiz J, et al. Safe use of liver donors with positive hepatitis B core antibody. Liver Transplant 2002; 8:556-561.
9. Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transplant 2001; 7:51-58.
10. Roque-Afonso AM, Feray C, Samuel D, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors. Gut 2002; 50:95-99.
11. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transplant 2004; 10:S74-S85.
12. Dodson SF, Bonham CA, Geller DA, et al. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68:1058-1061.
13. Fabrega E, Garcia-Suarez C, Guerra A, et al. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transplant 2003; 9:916-920.
14. Yu AS, Vierling JM, Colquhoun SD, et al. Transmission of hepatitis B infection from hepatitis B core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transplant 2001; 7:513-517.
15. Van Thiel DH, el-Ashmawy L, Love K, et al. Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci 1992; 37:1245-1249.
16. Chalasani N, Smallwood G, Halcomb J, et al. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transplant Surg 1998; 4:128-132.
17. Kallinowski B, Benz C, Buchholz L, Stremmel W. Accelerated schedule of hepatitis B vaccination in liver transplant candidates. Transplant Proc 1998; 30:797-799.
18. Horlander JC, Boyle N, Manam R, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999; 318:304-307.
19. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000; 14 (suppl):59B-62B.
20. Lemon S, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997; 336:196-214.
21. Nowicki MJ, Tong MJ, Bohman RE. Alterations in the immune response of nonresponders to hepatitis B vaccine. J Infect Dis 1985; 152:1245-1248.
22. Shaw FE, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. Vaccine 1989; 7:425-430.
23. Seaworth B, Drucker J, Starling J, et al. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 1988; 157:332-337.
24. Rosman AS, Basu P, Galvin K, Lieber CS. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients A randomized clinical trial. Am J Med 1997; 103:217-222.
25. Domínguez M, Bárcena R, García M, et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplantation waiting list. Liver Transplant 2000; 6:440-442.
26. Engler SH, Sauer PW, Golling M, et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol 2001; 13:363-367.
27. Milich DR, Thornton GB, Neurath AR, et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 1985; 228:1195-1198.
28. Milich DR, McLachlan A, Chisari FV, et al. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a preS(1) specific T-cell response can bypass nonresponsiveness to the pre-S(2) and S regions of the HBsAg. J Immunol 1986; 137:315-322.
29. Milich DR, McLachlan A, Chisari FV, et al. Immune response to the pre-S1 region of the hepatitis B surface antigen (HBsAg): a pre-S1 specific T cell response can bypass nonresponsiveness to the pre-S2 and S regions of HBsAg. J Immunol 1986; 137:315-322.
30. McDermott AB, Cohen SB, Zuckerman JN, Madrigal JA. Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine 1999; 17:330-339.
31. Aziz A, Aziz S, Li DS, et al. Efficacy of repeated high-dose hepatitis B vaccine (80 micro) in patients with chronic liver disease. J Viral Hepat 2006; 13:217-221. This study reports survival in recipients of HBsAg-positive liver grafts.
32. Hwang S, Lee SG, Park KM, et al. Five-year follow-up of a hepatitis B virus-positive recipient of hepatitis B surface antigen-positive living donor graft. Liver Transplant 2006; 12:993-997.
33. Gonzalez-Peralta RP, Andres JM, Tung FY, et al. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient. Transplantation 1994; 58:114-116.
34. Franchello A, Ghisetti V, Marzano A, et al. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transplant 2005; 11:922-928. This paper reports on the increased mortality associated with the use of HBsAg-positive donors for HSCT.
35. Lau GKK, Lie AKW, Kwong YL, et al. A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 2000; 96:452-458.
36. Locasciulli A, Alberti A, Bandini G, et al. Allogeneic bone marrow transplantation from HBsAg+ donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 1995; 86:3236-3240.
37. Chen PM, Fan S, Liu CJ, et al. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990; 49:708-713.
38. Fan FS, Tzeng CH, Yeh HM, Chen PM. Reverse seroconversion of hepatitis B virus infections status after allogeneic bone marrow transplantation from a carrier donor. Bone Marrow Transplant 1992; 10:189-191.
39. Rosendahl C, Bender-Goetze C, Deinhardt F, et al. Immunization against hepatitis B in BMT and leukemia patients. Exp Hematol 1985; 13 (Suppl 17):104-110.
40. Mangioni S, Balduzzi A, Rivolta A, et al. Long-term persistence of hematopoietic chimerism following sex-mismatched bone marrow transplantation. Bone Marrow Transplant 1997; 20:969-973.
41. Hui CK, Lie A, Au WY, et al. Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant 2005; 5:1437-1445.
42. Taludker MA, Gilmore R, Bachus RA. Prevalence of hepatitis B surface antigen among male Saudi Arabians. J Infect Dis 1982; 146:446.
43. Chan PC, Lok AS, Cheng IK, et al. The impact of donor and recipient hepatitis B surface antigen status on liver disease and survival in renal transplant recipients. Transplantation 1992; 53:128-131.
44. Veroux P, Veroux M, Sparacino V, et al. Kidney transplantation from donors with viral B and C hepatitis. Transplant Proc 2006; 38:996-998. This paper reports on the use of HBcAb-positive renal allografts.
45. Veroux M, Puliatti C, Gagliano D, et al. Use of hepatitis B core antibody-positive donor kidneys in hepatitis B surface antibody-positive and -negative recipients. Transplant Proc 2006; 81:2574-2575.
46. De Feo TM, Grossi P, Poli F, et al. Kidney transplantation from anti-HBc+ donors: results from a retrospective Italian study. Transplantation 2006; 81:76-80.
47. Lo CM, Fan ST, Liu CL, et al. Safety and outcome of hepatitis B core antibody-positive donors in right lobe living donor liver transplantation. Liver Transplant 2003; 9:827-832.